Characteristics and mutation analysis of Ph-positive leukemia patients with T315I mutation receiving tyrosine kinase inhibitors

BACKGROUND: TKIs are the first-line treatment for patients with Ph-positive (Ph+) leukemia. However, drug resistance is frequently observed, mainly due to mutations within the breakpoint cluster region-Abelson leukemia virus (BCR-ABL) kinase domain. The T315I substitution confers complete resistance...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Onco Targets Ther
Hlavní autoři: Xu, Peipei, Guo, Dan, Shao, Xiaoyan, Peng, Miaoxin, Chen, Bing
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2017
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5626416/
https://ncbi.nlm.nih.gov/pubmed/29026321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S142482
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky